You just read:

Janssen Presents New Data Showing INVOKANA® (canagliflozin) is Associated with Greater Blood Glucose Control and Treatment Adherence Compared to DPP-4 Inhibitors

News provided by

Janssen Pharmaceuticals, Inc.

11 Jun, 2016, 11:05 ET